Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy
We evaluated the effect of intravitreal bevacizumab injection (IVB) on choroidal thickness, and studied its association with the therapeutic response in chronic central serous chorioretinopathy (CSC). The clinical features of 78 eyes with chronic CSC treated with IVB from October 2014 to June 2020 w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/12/3375 |
| _version_ | 1797486005024980992 |
|---|---|
| author | Yoo-Ri Chung Su Jeong Lee Ji Hun Song |
| author_facet | Yoo-Ri Chung Su Jeong Lee Ji Hun Song |
| author_sort | Yoo-Ri Chung |
| collection | DOAJ |
| description | We evaluated the effect of intravitreal bevacizumab injection (IVB) on choroidal thickness, and studied its association with the therapeutic response in chronic central serous chorioretinopathy (CSC). The clinical features of 78 eyes with chronic CSC treated with IVB from October 2014 to June 2020 were retrospectively evaluated. Visual acuity (VA), central retinal thickness (CRT), and sub-foveal choroidal thickness (SFCT) were analyzed at baseline, 1 month following initial IVB, and the last follow-up examination. Cases showing complete recovery (resolved eyes; <i>n</i> = 60) were compared with those with persistent subretinal fluid (refractory eyes; <i>n</i> = 18). The relationship between the potential risk factors and subretinal fluid resolution was examined using logistic regression. SFCT was significantly decreased along with the CRT following IVB at the resolved state. SFCT reduction following 1 month of IVB was notably greater in the resolved eyes. The association of refractory eyes with hypertension (<i>p</i> = 0.003) and a thinner baseline SFCT (<i>p</i> = 0.024) was significant. In most of the patients with chronic CSC, VA and CRT remarkably improved following treatment with IVB. Early changes in the SFCT following IVB were associated with the therapeutic response. Patients with hypertension and a thinner baseline SFCT could be unresponsive to IVB. |
| first_indexed | 2024-03-09T23:27:56Z |
| format | Article |
| id | doaj.art-0ff66460b3b744b48acb60c387c7bf9f |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T23:27:56Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-0ff66460b3b744b48acb60c387c7bf9f2023-11-23T17:14:57ZengMDPI AGJournal of Clinical Medicine2077-03832022-06-011112337510.3390/jcm11123375Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous ChorioretinopathyYoo-Ri Chung0Su Jeong Lee1Ji Hun Song2Department of Ophthalmology, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Ophthalmology, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Ophthalmology, Ajou University School of Medicine, Suwon 16499, KoreaWe evaluated the effect of intravitreal bevacizumab injection (IVB) on choroidal thickness, and studied its association with the therapeutic response in chronic central serous chorioretinopathy (CSC). The clinical features of 78 eyes with chronic CSC treated with IVB from October 2014 to June 2020 were retrospectively evaluated. Visual acuity (VA), central retinal thickness (CRT), and sub-foveal choroidal thickness (SFCT) were analyzed at baseline, 1 month following initial IVB, and the last follow-up examination. Cases showing complete recovery (resolved eyes; <i>n</i> = 60) were compared with those with persistent subretinal fluid (refractory eyes; <i>n</i> = 18). The relationship between the potential risk factors and subretinal fluid resolution was examined using logistic regression. SFCT was significantly decreased along with the CRT following IVB at the resolved state. SFCT reduction following 1 month of IVB was notably greater in the resolved eyes. The association of refractory eyes with hypertension (<i>p</i> = 0.003) and a thinner baseline SFCT (<i>p</i> = 0.024) was significant. In most of the patients with chronic CSC, VA and CRT remarkably improved following treatment with IVB. Early changes in the SFCT following IVB were associated with the therapeutic response. Patients with hypertension and a thinner baseline SFCT could be unresponsive to IVB.https://www.mdpi.com/2077-0383/11/12/3375bevacizumabcentral serous chorioretinopathychoroidal thickness |
| spellingShingle | Yoo-Ri Chung Su Jeong Lee Ji Hun Song Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy Journal of Clinical Medicine bevacizumab central serous chorioretinopathy choroidal thickness |
| title | Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy |
| title_full | Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy |
| title_fullStr | Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy |
| title_full_unstemmed | Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy |
| title_short | Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy |
| title_sort | changes in the choroidal thickness following intravitreal bevacizumab injection in chronic central serous chorioretinopathy |
| topic | bevacizumab central serous chorioretinopathy choroidal thickness |
| url | https://www.mdpi.com/2077-0383/11/12/3375 |
| work_keys_str_mv | AT yoorichung changesinthechoroidalthicknessfollowingintravitrealbevacizumabinjectioninchroniccentralserouschorioretinopathy AT sujeonglee changesinthechoroidalthicknessfollowingintravitrealbevacizumabinjectioninchroniccentralserouschorioretinopathy AT jihunsong changesinthechoroidalthicknessfollowingintravitrealbevacizumabinjectioninchroniccentralserouschorioretinopathy |